Multiple Therapies Show Responses in Lung Cancer With ROS1 Fusions

August 03, 2020

Ben Levy, MD, discusses the mechanism of resistance such as the G2032R solvent front mutation in patients who received crizotinib for lung cancer with ROS1 fusions and how to treat them.

A 67-Year-Old Woman With Differentiated Thyroid Cancer

August 03, 2020

Lori Wirth, MD, provides insight on the case of a 67-year-old woman with differentiated thyroid cancer and examines the management of radioiodine-refractory disease.

Treatment Landscape for Acute Myeloid Leukemia Appears Hopeful for Patients

July 31, 2020

Eunice Wang, MD, discusses the excitement she has experienced in the treatment landscape of acute myeloid leukemia over the last several years due to the number of new treatment options approved by the FDA.

Targeted Therapy in Early-Stage HER2+ Breast Cancer

July 31, 2020

Experts from Sarah Cannon Research Institute talk about the expanding role of targeted treatment options in early HER2+ breast cancer.

Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

July 30, 2020

Ian E. Krop, MD, PhD, discusses the importance of clinical trials further exploring the role of trastuzumab deruxtecan following the FDA’s approval of the agent as treatment of patients with HER2-positive metastatic breast cancer.

Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20

July 29, 2020

Leora Horn, MD, MSc, discusses the real-world data outcomes compared with clinical trial data of mobocertinib from a retrospective study in patients with refractory non–small cell lung cancer with EGFR exon 20 insertions.

Study Investigates Hydroxychloroquine and Itraconazole in Ovarian Cancer

July 28, 2020

Ainhoa Madariaga, MD, discusses the data from the phase 1/2 HYDRA-01 trial looking at hydroxychloroquine and itraconazole in patients with advanced platinum-resistant epithelial ovarian cancer.

Larotrectinib Is Well-Tolerated in Metastatic Solid Tumors

July 28, 2020

Marcia Brose, MD, PhD, discusses the safety findings from an analysis of larotrectinib as treatment of patients with metastatic solid tumors.

Advancing Survival in Relapsed/Refractory Multiple Myeloma

July 28, 2020

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Results of Pooled Analysis Show Positive Data for Trilaciclib in ES-SCLC

July 27, 2020

Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.